Literature DB >> 11430999

Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders.

R Gold1, F Buttgereit, K V Toyka.   

Abstract

Glucocorticosteroids are the most potent immunosuppressive and antiinflammatory drugs. Over the six decades that have passed since their discovery, a variety of genomic effector mechanisms of steroid hormones has been described which are mediated by the cytosolic steroid receptor. Recent evidence supports a direct effect of glucocorticosteroids on cellular membranes that occurs at higher hormone concentrations, termed nongenomic effects. These imply a qualitatively distinct mode of steroid action leading to cellular apoptosis. In this review, we discuss in vitro and in vivo data on nongenomic effects of glucocorticosteroids and their possible implications for the therapy of human neuroimmunological diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11430999     DOI: 10.1016/s0165-5728(01)00330-7

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  25 in total

1.  Experimental herpes simplex virus encephalitis: a combination therapy of acyclovir and glucocorticoids reduces long-term magnetic resonance imaging abnormalities.

Authors:  Uta K Meyding-Lamadé; Christoph Oberlinner; Philipp R Rau; Sonja Seyfer; Sabine Heiland; Johann Sellner; Brigitte T Wildemann; Wolfram R Lamadé
Journal:  J Neurovirol       Date:  2003-02       Impact factor: 2.643

2.  Controlled release of triamcinolone acetonide from polyurethane implantable devices: application for inhibition of inflammatory-angiogenesis.

Authors:  Flávia Carmo Horta Pinto; Armando Da Silva-Cunha Junior; Rodrigo Lambert Oréfice; Eliane Ayres; Silvia Passos Andrade; Luiza Dias C Lima; Sandra A Lima Moura; Gisele Rodrigues Da Silva
Journal:  J Mater Sci Mater Med       Date:  2012-04-01       Impact factor: 3.896

Review 3.  Corticosteroids and plasma exchange in multiple sclerosis.

Authors:  Hayretin Tumani
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

Review 4.  Escalating immunotherapy of multiple sclerosis--new aspects and practical application.

Authors:  P Rieckmann; K V Toyka; C Bassetti; K Beer; S Beer; U Buettner; M Chofflon; M Götschi-Fuchs; K Hess; L Kappos; J Kesselring; N Goebels; H-P Ludin; H Mattle; M Schluep; C Vaney; U Baumhackl; T Berger; F Deisenhammer; F Fazekas; M Freimüller; H Kollegger; W Kristoferitsch; H Lassmann; H Markut; S Strasser-Fuchs; K Vass; H Altenkirch; S Bamborschke; K Baum; R Benecke; W Brück; D Dommasch; W G Elias; A Gass; W Gehlen; J Haas; G Haferkamp; F Hanefeld; H-P Hartung; C Heesen; F Heidenreich; R Heitmann; B Hemmer; T Hense; R Hohlfeld; R W C Janzen; G Japp; S Jung; E Jügelt; J Koehler; W Kölmel; N König; K Lowitzsch; U Manegold; A Melms; J Mertin; P Oschmann; H-F Petereit; M Pette; D Pöhlau; D Pohl; S Poser; M Sailer; S Schmidt; G Schock; M Schulz; S Schwarz; D Seidel; N Sommer; M Stangel; E Stark; A Steinbrecher; H Tumani; R Voltz; F Weber; W Weinrich; R Weissert; H Wiendl; H Wiethölter; U Wildemann; U K Zettl; F Zipp; R Zschenderlein; G Izquierdo; A Kirjazovas; L Packauskas; D Miller; B Koncan Vracko; A Millers; A Orologas; M Panellus; C J M Sindic; M Bratic; A Svraka; N R Vella; Z Stelmasiak; K Selmaj; H Bartosik-Psujik; K Mitosek-Szewczyk; E Belniak; A Mochecka; A Bayas; A Chan; P Flachenecker; R Gold; B Kallmann; V Leussink; M Mäurer; K Ruprecht; G Stoll; F X Weilbach
Journal:  J Neurol       Date:  2004-11       Impact factor: 4.849

5.  Ozone Therapy in Ethidium Bromide-Induced Demyelination in Rats: Possible Protective Effect.

Authors:  Neveen A Salem; Naglaa Assaf; Manal F Ismail; Yasser A Khadrawy; Mohga Samy
Journal:  Cell Mol Neurobiol       Date:  2015-10-14       Impact factor: 5.046

6.  Effect of combined treatment with methylprednisolone and soluble Nogo-66 receptor after rat spinal cord injury.

Authors:  Benxiu Ji; Mingwei Li; Stephane Budel; R Blake Pepinsky; Lee Walus; Thomas M Engber; Stephen M Strittmatter; Jane K Relton
Journal:  Eur J Neurosci       Date:  2005-08       Impact factor: 3.386

7.  Management of acute exacerbations in multiple sclerosis.

Authors:  Daniel Ontaneda; Alex D Rae-Grant
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

8.  [Steroids for optic nerve diseases?].

Authors:  W A Lagrèze
Journal:  Ophthalmologe       Date:  2007-06       Impact factor: 1.059

9.  Mathematical modeling of corticosteroid pharmacogenomics in rat muscle following acute and chronic methylprednisolone dosing.

Authors:  Zhenling Yao; Eric P Hoffman; Svetlana Ghimbovschi; Debra C Dubois; Richard R Almon; William J Jusko
Journal:  Mol Pharm       Date:  2008-02-14       Impact factor: 4.939

Review 10.  Corticosteroids for multiple sclerosis: I. Application for treating exacerbations.

Authors:  Elliot M Frohman; Anjali Shah; Eric Eggenberger; Luanne Metz; Robert Zivadinov; Olaf Stüve
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.